Phase I trial of pegylated interferon-α-2b in young patients with plexiform neurofibromas
- 18 January 2011
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 76 (3) , 265-272
Abstract
Objective: Interferon has antiproliferative and antiangiogenic properties. We sought to evaluate preliminary efficacy and determine the recommended phase II dose (RP2D) for pegylated interferon-α-2b (PI) in patients with unresectable progressive or symptomatic plexiform neurofibromas (PN). Methods: PI was administered weekly in cohorts of 3–6 patients during the dose-finding phase and continued for up to 2 years. Twelve patients were treated at the RP2D to further evaluate toxicity and activity. Results: Thirty patients (median age 9.3 years, range 1.9–34.7 years) were enrolled. No dose-limiting toxicity (DLT) was seen in patients treated at the 3 μg/kg dose level (DL) during the first 4 weeks. All 5 patients treated at the 4.5 μg/kg DL came off study or required dose reductions for behavioral toxicity or fatigue. Similar DLT on the 3 μg/kg DL became apparent over time. There was 1 DLT (myoclonus) in 12 patients enrolled at the 1.0 μg/kg DL. Eleven of 16 patients with pain showed improvement and 13 of 14 patients with a palpable mass had a decrease in size. Five of 17 patients (29%) who underwent volumetric analysis had a 15%–22% decrease in volume. Three of 4 patients with documented radiographic progression prior to enrollment showed stabilization or shrinkage. Conclusions: The RP2D of PI for pediatric patients with PN is 1 μg/kg/wk. Clinical and radiographic improvement and cessation of growth can occur. Classification of evidence: This study provides Class III evidence that pegylated interferon-α-2b in patients with unresectable, progressive, symptomatic, or life-threatening PNs results in radiographic reduction or stabilization of PN size.Keywords
This publication has 23 references indexed in Scilit:
- Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromasNeurology, 2009
- Phase I Trial of Pirfenidone in Children with Neurofibromatosis 1 and Plexiform NeurofibromasPediatric Neurology, 2007
- Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groupsBlood, 2004
- Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trialsCancer Treatment Reviews, 2003
- Peginterferon Alfa-2a in Patients with Chronic Hepatitis CNew England Journal of Medicine, 2000
- A prospective 10 year follow up study of patients with neurofibromatosis type 1Archives of Disease in Childhood, 1998
- Neurofibromatosis Type 1—An Update and Review for the Primary PediatricianClinical Pediatrics, 1996
- Peripheral nerve sheath tumors histogenesis, classification, and prognosisCancer, 1993
- Interferon Alfa-2a Therapy for Life-Threatening Hemangiomas of InfancyNew England Journal of Medicine, 1992
- The therapeutic value of poly(ethylene glycol)-modified proteinsAdvanced Drug Delivery Reviews, 1991